Multiple Myeloma Overview

Multiple myeloma is the second most prevalent hematological malignancy, with over 55,000 new cases diagnosed each year.

About the Text

This exciting new text, edited by lauded authorities on the topic, stands as the only available reference to assemble, review, and synthesize the latest studies on translational therapies.

Content Highlights

It clearly explains the impact of molecular pathogenesis, biology, and prognostic factors on the diagnosis, prognosis, and individualization of treatment.

It also covers the development of novel therapeutic options for patients with myeloma.